JP2001518073A5 - - Google Patents

Download PDF

Info

Publication number
JP2001518073A5
JP2001518073A5 JP1998526985A JP52698598A JP2001518073A5 JP 2001518073 A5 JP2001518073 A5 JP 2001518073A5 JP 1998526985 A JP1998526985 A JP 1998526985A JP 52698598 A JP52698598 A JP 52698598A JP 2001518073 A5 JP2001518073 A5 JP 2001518073A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP1998526985A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001518073A (ja
JP4275741B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1997/022815 external-priority patent/WO1998025963A1/en
Publication of JP2001518073A publication Critical patent/JP2001518073A/ja
Publication of JP2001518073A5 publication Critical patent/JP2001518073A5/ja
Application granted granted Critical
Publication of JP4275741B2 publication Critical patent/JP4275741B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP52698598A 1996-12-13 1997-12-12 血小板由来増殖因子タンパク質の分析および分離 Expired - Lifetime JP4275741B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3272096P 1996-12-13 1996-12-13
US60/032,720 1996-12-13
PCT/US1997/022815 WO1998025963A1 (en) 1996-12-13 1997-12-12 Analysis and separation of platelet-derived growth factor proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2007208669A Division JP2008031173A (ja) 1996-12-13 2007-08-09 血小板由来増殖因子タンパク質の分析および分離

Publications (3)

Publication Number Publication Date
JP2001518073A JP2001518073A (ja) 2001-10-09
JP2001518073A5 true JP2001518073A5 (cg-RX-API-DMAC10.html) 2005-08-11
JP4275741B2 JP4275741B2 (ja) 2009-06-10

Family

ID=21866458

Family Applications (4)

Application Number Title Priority Date Filing Date
JP52692698A Expired - Fee Related JP4341859B2 (ja) 1996-12-13 1997-12-12 酵母での異種タンパク質の発現の方法
JP52698598A Expired - Lifetime JP4275741B2 (ja) 1996-12-13 1997-12-12 血小板由来増殖因子タンパク質の分析および分離
JP2007208669A Withdrawn JP2008031173A (ja) 1996-12-13 2007-08-09 血小板由来増殖因子タンパク質の分析および分離
JP2007338286A Withdrawn JP2008119008A (ja) 1996-12-13 2007-12-27 酵母での異種タンパク質の発現の方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP52692698A Expired - Fee Related JP4341859B2 (ja) 1996-12-13 1997-12-12 酵母での異種タンパク質の発現の方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2007208669A Withdrawn JP2008031173A (ja) 1996-12-13 2007-08-09 血小板由来増殖因子タンパク質の分析および分離
JP2007338286A Withdrawn JP2008119008A (ja) 1996-12-13 2007-12-27 酵母での異種タンパク質の発現の方法

Country Status (9)

Country Link
US (10) US6017731A (cg-RX-API-DMAC10.html)
EP (4) EP0948538B1 (cg-RX-API-DMAC10.html)
JP (4) JP4341859B2 (cg-RX-API-DMAC10.html)
AT (3) ATE253120T1 (cg-RX-API-DMAC10.html)
AU (2) AU5794598A (cg-RX-API-DMAC10.html)
DE (3) DE69739319D1 (cg-RX-API-DMAC10.html)
ES (1) ES2306462T3 (cg-RX-API-DMAC10.html)
PT (1) PT948538E (cg-RX-API-DMAC10.html)
WO (2) WO1998025963A1 (cg-RX-API-DMAC10.html)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0561137B1 (en) 1983-04-25 2002-07-03 Chiron Corporation Hybrid DNA Synthesis of Mature Insulin-like Growth Factors
US5811381A (en) * 1996-10-10 1998-09-22 Mark A. Emalfarb Cellulase compositions and methods of use
US7883872B2 (en) * 1996-10-10 2011-02-08 Dyadic International (Usa), Inc. Construction of highly efficient cellulase compositions for enzymatic hydrolysis of cellulose
US6017731A (en) * 1996-12-13 2000-01-25 Chiron Corporation Method for expression of heterologous proteins in yeast
DK1117808T3 (da) * 1998-10-06 2005-04-25 Mark Aaron Emalfarb Transformaationssystem inden jfjor området filamentöse svampeværter: I chrysosporium
US20040146918A1 (en) * 2000-02-18 2004-07-29 Weiner Michael L. Hybrid nucleic acid assembly
US7166712B2 (en) 2000-07-12 2007-01-23 Philadelphia, Health And Education Corporation Mammalian MDM2 binding proteins and uses thereof
WO2005011619A2 (en) * 2003-01-31 2005-02-10 Five Prime Therapeutics, Inc. Lung-expressed polypeptides
CN108486086A (zh) 2003-07-02 2018-09-04 维莱尼姆公司 葡聚糖酶，编码它们的核酸以及制备和使用它们的方法
DE10342794A1 (de) * 2003-09-16 2005-04-21 Basf Ag Sekretion von Proteinen aus Hefen
CA2548140A1 (en) 2003-12-05 2005-06-23 University Of Massachusetts Oligosaccharide compositions and use thereof in the treatment of infection
NZ548255A (en) 2004-02-02 2010-10-29 Ambrx Inc Modified human interferon polypeptides and their uses
CN102603895B (zh) 2004-06-18 2016-09-28 Ambrx公司 新颖抗原结合多肽和其用途
BRPI0512396A (pt) * 2004-07-21 2008-03-11 Ambrx Inc polipeptìdeos biossintéticos utilizando aminoácidos codificados não naturalmente
US7473678B2 (en) 2004-10-14 2009-01-06 Biomimetic Therapeutics, Inc. Platelet-derived growth factor compositions and methods of use thereof
KR20070090023A (ko) * 2004-12-22 2007-09-04 암브룩스, 인코포레이티드 변형 인간 성장 호르몬
NZ555308A (en) 2004-12-22 2010-10-29 Ambrx Inc Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
BRPI0519170A8 (pt) 2004-12-22 2018-05-08 Ambrx Inc formulações de hormônio de crescimento humano que compreendem um aminoácido não naturalmente codificado
CN102732588B (zh) * 2004-12-22 2015-01-07 Ambrx公司 氨酰基-tRNA合成酶的组合物及其用途
BRPI0518661A2 (pt) 2004-12-22 2008-12-02 Ambrx Inc mÉtodos para expressço e purificaÇço do hormânio do crescimento humano recombinante
JP2008541769A (ja) * 2005-06-03 2008-11-27 アンブレツクス・インコーポレイテツド 改善されたヒトインターフェロン分子及びそれらの使用
US20070048793A1 (en) * 2005-07-12 2007-03-01 Baynes Brian M Compositions and methods for biocatalytic engineering
CN103103238B (zh) 2005-08-18 2016-08-10 Ambrx公司 一种在细胞中制造在特定位置处具有所选氨基酸的抗体或抗体片段多肽的方法
FR2891149B1 (fr) 2005-09-26 2007-11-30 Biodex Sarl Composition pharmaceutique a action cicatrisante comprenant un derive de dextrane soluble et un facteur de croissance derive des plaquettes.
PL1954710T3 (pl) * 2005-11-08 2011-09-30 Ambrx Inc Przyspieszacze do modyfikacji aminokwasów niewystępujących w przyrodzie i polipeptydów zbudowanych z aminokwasów nie występujących w przyrodzie
ES2547554T3 (es) 2005-11-16 2015-10-07 Ambrx, Inc. Métodos y composiciones que comprenden aminoácidos no naturales
BRPI0618794A2 (pt) * 2005-11-17 2011-09-13 Biomimetic Therapeutics Inc uso de uma matriz biocompatìvel, kit e composição para aumento ósseo, especialmente para aumento do osso maxilofacial
WO2007070659A2 (en) * 2005-12-14 2007-06-21 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
ES2443581T3 (es) 2006-02-09 2014-02-19 Biomimetic Therapeutics, Llc Composiciones y métodos para el tratamiento de hueso
US9161967B2 (en) 2006-06-30 2015-10-20 Biomimetic Therapeutics, Llc Compositions and methods for treating the vertebral column
WO2008005427A2 (en) 2006-06-30 2008-01-10 Biomimetic Therapeutics, Inc. Pdgf-biomatrix compositions and methods for treating rotator cuff injuries
MX2009002526A (es) * 2006-09-08 2009-04-16 Ambrx Inc Transcripcion de tarn supresor en celulas de vertebrados.
EP2061878B1 (en) * 2006-09-08 2014-01-08 Ambrx, Inc. Hybrid suppressor trna for vertebrate cells
MX2009002523A (es) 2006-09-08 2009-03-20 Ambrx Inc Polipeptido de plasma humano modificado o andamios fc y sus usos.
AU2007333425B2 (en) 2006-11-03 2014-03-27 Stryker Corporation Compositions and methods for arthrodetic procedures
EP2505651A3 (en) 2006-12-10 2013-01-09 Dyadic International, Inc. Isolated fungus with reduced protease activity
US9862956B2 (en) 2006-12-10 2018-01-09 Danisco Us Inc. Expression and high-throughput screening of complex expressed DNA libraries in filamentous fungi
AU2008232937B2 (en) 2007-03-30 2012-09-27 Ambrx, Inc. Modified FGF-21 polypeptides and their uses
JP2010525821A (ja) 2007-05-02 2010-07-29 アンブルックス，インコーポレイテッド 修飾ＩＦＮβポリペプチドおよびこれらの使用
US8551751B2 (en) * 2007-09-07 2013-10-08 Dyadic International, Inc. BX11 enzymes having xylosidase activity
EP2217265B1 (en) 2007-11-20 2017-05-10 Ambrx, Inc. Modified insulin polypeptides and their uses
CN105854074B (zh) 2008-02-07 2019-10-15 生物模拟治疗有限责任公司 用于牵引成骨术的组合物和方法
NZ586947A (en) 2008-02-08 2012-11-30 Ambrx Inc Modified leptin polypeptides and their uses
UA103774C2 (uk) 2008-07-23 2013-11-25 Амбркс, Інк. Модифіковані поліпептиди бичачого гранулоцитарного колонієстимулювального фактора (g-csf) та їх застосування
NZ602861A (en) 2008-09-09 2014-03-28 Biomimetic Therapeutics Llc Platelet-derived growth factor compositions and methods for the treatment of tendon and ligament injuries
BR122012024318A2 (pt) 2008-09-26 2019-07-30 Ambrx, Inc. Polipeptídeos modificados de eritropoetina animal e seus usos
MX357314B (es) 2008-09-26 2018-07-04 Ambrx Inc Microorganismos y vacunas dependientes de replicacion de aminoacidos no naturales.
US8183346B2 (en) * 2008-12-05 2012-05-22 Eli Lilly And Company Anti-ferroportin 1 monoclonal antibodies and uses thereof
EP2805965A1 (en) 2009-12-21 2014-11-26 Ambrx, Inc. Modified porcine somatotropin polypeptides and their uses
JP2013515080A (ja) 2009-12-21 2013-05-02 アンブルックス，インコーポレイテッド 修飾されているウシのソマトトロピンポリペプチドおよびそれらの使用
NZ601559A (en) 2010-02-22 2014-10-31 Biomimetic Therapeutics Llc Platelet-derived growth factor compositions and methods for the treatment of tendinopathies
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
SMT201900495T1 (it) 2010-08-17 2019-11-13 Ambrx Inc Polipeptidi di relaxina modificati e loro usi
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
CN105085652B (zh) 2014-05-16 2021-06-22 中国人民解放军军事医学科学院生物工程研究所 血小板衍生生长因子b突变体、其制备方法及用途
MX2017004520A (es) * 2014-10-14 2018-03-15 Lynch Samuel Composiciones para tratar heridas.
CN114805531A (zh) 2014-10-24 2022-07-29 百时美施贵宝公司 修饰的fgf-21多肽及其用途
CN106496302B (zh) * 2015-09-08 2021-12-10 三生国健药业（上海）股份有限公司 一种用离子交换层析纯化蛋白质的方法
CN108239648B (zh) * 2016-12-26 2023-04-07 丰益(上海)生物技术研发中心有限公司 高效表达米黑根毛霉脂肪酶的方法
TW201837051A (zh) 2017-02-08 2018-10-16 美商必治妥美雅史谷比公司 包含藥物動力學增強劑之經修飾之鬆弛素(relaxin)多肽及其用途
CN110590930B (zh) * 2018-06-13 2023-03-31 四川好医生攀西药业有限责任公司 美洲大蠊生长因子pdgf在制备损伤修复药物中的应用
US20210388037A1 (en) * 2018-11-19 2021-12-16 Basf Se Leader sequence for yeast

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2359180A (en) * 1942-08-11 1944-09-26 Gen Motors Corp Dynamic balancer
NZ201918A (en) 1981-09-18 1987-04-30 Genentech Inc N-terminal methionyl analogues of bovine growth hormone
US5010003A (en) * 1983-04-25 1991-04-23 Genentech, Inc. Use of yeast homologous signals to secrete heterologous proteins
US4769328A (en) * 1984-10-12 1988-09-06 Zymogenetics Inc. Expression of biologically active PDGF analogs in yeast
US4849407A (en) 1986-08-13 1989-07-18 Zymogenetics, Inc. Biologically active mosaic proteins
US4801542A (en) 1984-10-12 1989-01-31 Zymogenetics, Inc. Expression of biologically active PDGF analogs in eucaryotic cells
US4766073A (en) * 1985-02-25 1988-08-23 Zymogenetics Inc. Expression of biologically active PDGF analogs in eucaryotic cells
US5187263A (en) 1984-10-12 1993-02-16 Zymogenetics, Inc. Expression of biologically active PDGE analogs in eucaryotic cells
EP0487116B1 (en) * 1984-10-12 1999-12-29 ZymoGenetics, Inc. Biologically active PDGF analogs in eucaryotic cells
US5516896A (en) * 1985-02-25 1996-05-14 Zymogenetics, Inc. Biologically active B-chain homodimers
US5045633A (en) 1985-02-25 1991-09-03 Zymogenetics, Inc. Expression of biologically active PDGF analogs in eucaryotic cells
AU5912586A (en) * 1985-06-20 1986-12-24 Salk Institute Biotechnology/Industrial Associates, Inc., The Alpha-factor leader peptide-facilitated secretion from transformed s cerevisiae
ATE131532T1 (de) * 1986-08-13 1995-12-15 Zymogenetics Inc Expression von biologisch-aktiven pdgf-analogen in eukaryotischen zellen
IE60517B1 (en) 1986-11-14 1994-07-27 Inst Molecular Biology Inc Wound healing and bone regeneration
US5019559A (en) 1986-11-14 1991-05-28 President And Fellows Of Harvard College Wound healing using PDGF and IGF-II
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US5219759A (en) 1987-04-22 1993-06-15 Chiron Corporation Recombinant DNA encoding PDGF A-chain polypeptide and expression vectors
CA1340772C (en) * 1987-12-30 1999-09-28 Patricia Tekamp-Olson Expression and secretion of heterologous protiens in yeast employing truncated alpha-factor leader sequences
US5094941A (en) * 1987-12-31 1992-03-10 Zymogenetics, Inc. Monoclonal antibodies to PDGF
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
DK105489D0 (da) * 1989-03-03 1989-03-03 Novo Nordisk As Polypeptid
DE3900770A1 (de) * 1989-01-12 1990-07-26 Juergen Prof Dr Hoppe Verfahren zur herstellung von pdgf-a und pdgf-aa
US5968778A (en) * 1989-01-12 1999-10-19 Jurgen Hoppe PDGF-AB, preparation process and pharmaceuticals containing them
ZA911974B (en) 1990-03-21 1994-08-22 Res Dev Foundation Heterovesicular liposomes
DE69031218T2 (de) 1990-04-10 1997-12-11 Harvard College Wundheilung
US5962219A (en) * 1990-06-11 1999-10-05 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-selex
DK0547064T3 (da) * 1990-07-23 1995-03-20 Zymogenetics Inc Proteaseresistent PDGF og anvendelsesfremgangsmåde
WO1992007065A1 (en) * 1990-10-12 1992-04-30 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Modified ribozymes
DK300090D0 (da) * 1990-12-19 1990-12-19 Novo Nordisk As Fremgangsmaade til fremstilling af leadersekvenser
DE4216134A1 (de) * 1991-06-20 1992-12-24 Europ Lab Molekularbiolog Synthetische katalytische oligonukleotidstrukturen
WO1993008825A1 (en) 1991-11-04 1993-05-13 Zymogenetics, Inc. Pdgf gel formulation
ATE312188T1 (de) * 1993-01-22 2005-12-15 Univ Research Corp Lokalisierung von therapeutischen mitteln
JP3545403B2 (ja) 1993-04-22 2004-07-21 スカイファルマ インコーポレイテッド 医薬化合物を被包しているシクロデキストリンリポソーム及びその使用法
DK82893D0 (da) * 1993-07-08 1993-07-08 Novo Nordisk As Peptid
US5624803A (en) * 1993-10-14 1997-04-29 The Regents Of The University Of California In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom
CA2176712C (en) 1993-11-16 2000-05-23 Mantripragada Sankaram Synthetic membrane vesicles with controlled release of encapsulated biologically active substances
US5902880A (en) * 1994-08-19 1999-05-11 Ribozyme Pharmaceuticals, Inc. RNA polymerase III-based expression of therapeutic RNAs
US5627053A (en) * 1994-03-29 1997-05-06 Ribozyme Pharmaceuticals, Inc. 2'deoxy-2'-alkylnucleotide containing nucleic acid
DE69535703T2 (de) * 1994-04-13 2009-02-19 The Rockefeller University AAV-vermittelte Zufuhr von DNA an Zellen des Nervensystems
US5639642A (en) * 1994-06-16 1997-06-17 Novo Nordisk A/S Synthetic leader peptide sequences
ZA954983B (en) * 1994-06-17 1996-02-14 Novo Nordisk As N-terminally extended proteins expressed in yeast
US6146886A (en) * 1994-08-19 2000-11-14 Ribozyme Pharmaceuticals, Inc. RNA polymerase III-based expression of therapeutic RNAs
US5716824A (en) * 1995-04-20 1998-02-10 Ribozyme Pharmaceuticals, Inc. 2'-O-alkylthioalkyl and 2-C-alkylthioalkyl-containing enzymatic nucleic acids (ribozymes)
ZA9610456B (en) * 1995-12-20 1997-06-20 Novo Nordisk As N-terminally extended proteins expressed in yeast
US5998203A (en) * 1996-04-16 1999-12-07 Ribozyme Pharmaceuticals, Inc. Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
US6017731A (en) * 1996-12-13 2000-01-25 Chiron Corporation Method for expression of heterologous proteins in yeast
US6248878B1 (en) * 1996-12-24 2001-06-19 Ribozyme Pharmaceuticals, Inc. Nucleoside analogs
US6001311A (en) * 1997-02-05 1999-12-14 Protogene Laboratories, Inc. Apparatus for diverse chemical synthesis using two-dimensional array
US6395713B1 (en) * 1997-07-23 2002-05-28 Ribozyme Pharmaceuticals, Inc. Compositions for the delivery of negatively charged molecules

Similar Documents

Publication Publication Date Title
JP2000502280A5 (cg-RX-API-DMAC10.html)
JP2000501771A5 (cg-RX-API-DMAC10.html)
JP2000501599A5 (cg-RX-API-DMAC10.html)
JP2000501018A5 (cg-RX-API-DMAC10.html)
JP2000500076A5 (cg-RX-API-DMAC10.html)
JP2000501324A5 (cg-RX-API-DMAC10.html)
JP2000502472A5 (cg-RX-API-DMAC10.html)
JP2000501825A5 (cg-RX-API-DMAC10.html)
JP2000501338A5 (cg-RX-API-DMAC10.html)
JP2000503414A5 (cg-RX-API-DMAC10.html)
JP2001518073A5 (cg-RX-API-DMAC10.html)
JP2000500874A5 (cg-RX-API-DMAC10.html)
JP2000502425A5 (cg-RX-API-DMAC10.html)
JP2000502485A5 (cg-RX-API-DMAC10.html)
JP2000502568A5 (cg-RX-API-DMAC10.html)
JP2000501774A5 (cg-RX-API-DMAC10.html)
JP2000500912A5 (cg-RX-API-DMAC10.html)
JP2000502570A5 (cg-RX-API-DMAC10.html)
JP2000501876A5 (cg-RX-API-DMAC10.html)
JP2000501744A5 (cg-RX-API-DMAC10.html)
JP2000501229A5 (cg-RX-API-DMAC10.html)
JP2000500857A5 (cg-RX-API-DMAC10.html)
JP2000502316A5 (cg-RX-API-DMAC10.html)
JP2000502714A5 (cg-RX-API-DMAC10.html)
JP2000501569A5 (cg-RX-API-DMAC10.html)